LOGIN  |  REGISTER
Chimerix

BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

April 30, 2024 | Last Trade: US$23.29 0.93 4.16

BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and give a general business update.

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-877-346-6112 or 1-848-280-6350 for international callers. A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.

Media & Investor Relations

At the Company
Troy Wichterman 
Chief Financial Officer
(425) 402-1400
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page